Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.43 |
| ▸ | ITGAL | P20701 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13226271 | 0.88 | RAB9A (0.57) | NPC1RAB9AITGB2ICAM1ITGAL | |
| SCHEMBL14454225 | 0.87 | NPC1 (0.51) | NPC1RAB9ACRBNTRPA1KMT2A | |
| SCHEMBL6989227 | 0.83 | RAB9A (0.43) | NPC1RAB9ACRBNITGB2ICAM1 | |
| SCHEMBL14454241 | 0.82 | NPC1 (0.53) | NPC1RAB9ACRBNITGB2ICAM1 | |
| SCHEMBL14454235 | 0.82 | NPC1 (0.53) | NPC1RAB9ACRBNITGB2ICAM1 | |
| SCHEMBL14454224 | 0.82 | ITGB2 (0.46) | NPC1RAB9ACRBNITGB2ICAM1 | |
| SCHEMBL15610734 | 0.82 | NPC1 (0.49) | NPC1RAB9ACRBNITGB2ICAM1 | |
| SCHEMBL15402236 | 0.81 | CFTR (0.43) | NPC1RAB9ACRBNCES2CES1 | |
| SCHEMBL17214431 | 0.81 | NPC1 (0.47) | NPC1RAB9AITGB2ICAM1ITGAL | |
| SCHEMBL1202579 | 0.81 | GAA (0.52) | NPC1RAB9ACRBNITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | HILL JASON | 2009-01-08 | — | — | US | disclosed |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CUBIST PHARMACEUTICALS, INC. | 2008-11-20 | — | — | US | disclosed |
| US-7408025-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-7335725-B2 | Lipopeptides as antibacterial agents | CUBIST PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050203006-A1 | Novel lipopeptides as antibacterial agents | MERCK SHARP & DOHME CORP. | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203006-A1 | Novel lipopeptides as antibacterial agents | CLPTM1, NGLY1, VIP | NPC1 1984/4885RAB9A 3163/4885CRBN 4603/4885 |
| US-20080287347-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | NPC1 1984/4885RAB9A 3163/4885CRBN 4603/4885 |
| US-20090011977-A1 | Novel Lipopeptides as Antibacterial Agents | CLPTM1, NGLY1, VIP | NPC1 1984/4885RAB9A 3163/4885CRBN 4603/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | NPC1 3306/4885RAB9A 826/4885CRBN 4457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.